Form 8-K - Current report:
SEC Accession No. 0001558370-20-008123
Filing Date
2020-07-14
Accepted
2020-07-14 06:27:49
Documents
13
Period of Report
2020-07-13
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K bpmc-20200713x8k.htm   iXBRL 8-K 47184
2 EX-99.1 bpmc-20200713xex99d1.htm EX-99.1 35142
  Complete submission text file 0001558370-20-008123.txt   212466

Data Files

Seq Description Document Type Size
3 EX-101.SCH bpmc-20200713.xsd EX-101.SCH 3241
4 EX-101.LAB bpmc-20200713_lab.xml EX-101.LAB 15501
5 EX-101.PRE bpmc-20200713_pre.xml EX-101.PRE 10530
6 EXTRACTED XBRL INSTANCE DOCUMENT bpmc-20200713x8k_htm.xml XML 4679
Mailing Address 45 SIDNEY STREET CAMBRIDGE MA 02139
Business Address 45 SIDNEY STREET CAMBRIDGE MA 02139 617-374-7580
Blueprint Medicines Corp (Filer) CIK: 0001597264 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37359 | Film No.: 201026276
SIC: 2834 Pharmaceutical Preparations